Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials |
| |
| Affiliation: | 2. Dermatology Centre, Salford Royal Hospital, University of Manchester, Manchester NIHR Biomedical Research Centre, Manchester, United Kingdom;3. Medical College of Wisconsin, Milwaukee, Wisconsin;4. K Papp Clinical Research and Probity Research, Inc, Waterloo, Ontario, Canada;5. Janssen Research & Development, LLC, Spring House, Pennsylvania;6. Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania;7. Department of Dermatology, Harvard Medical School, Boston, Massachusetts;8. University of Southern California, Los Angeles, California;9. The University of Melbourne, St. Vincent''s Hospital Melbourne and Probity Medical Research, Skin & Cancer Foundation Inc., Carlton, Victoria, Australia;10. Oregon Medical Research Center, Portland, Oregon |
| |
| Abstract: | |
| |
| Keywords: | adalimumab efficacy guselkumab long-term psoriasis safety VOYAGE 1 VOYAGE 2 AE" },{" #name" :" keyword" ," $" :{" id" :" kwrd0055" }," $$" :[{" #name" :" text" ," _" :" adverse event DLQI" },{" #name" :" keyword" ," $" :{" id" :" kwrd0065" }," $$" :[{" #name" :" text" ," _" :" Dermatology Life Quality Index HRQoL" },{" #name" :" keyword" ," $" :{" id" :" kwrd0075" }," $$" :[{" #name" :" text" ," _" :" health-related quality of life IGA" },{" #name" :" keyword" ," $" :{" id" :" kwrd0085" }," $$" :[{" #name" :" text" ," _" :" Investigator's Global Assessment IL" },{" #name" :" keyword" ," $" :{" id" :" kwrd0095" }," $$" :[{" #name" :" text" ," _" :" interleukin ISR" },{" #name" :" keyword" ," $" :{" id" :" kwrd0105" }," $$" :[{" #name" :" text" ," _" :" injection site reaction NRI" },{" #name" :" keyword" ," $" :{" id" :" kwrd0115" }," $$" :[{" #name" :" text" ," _" :" nonresponder imputation PASI" },{" #name" :" keyword" ," $" :{" id" :" kwrd0125" }," $$" :[{" #name" :" text" ," _" :" Psoriasis Area and Severity Index PASI 90" },{" #name" :" keyword" ," $" :{" id" :" kwrd0135" }," $$" :[{" #name" :" text" ," _" :" at least 90% improvement in Psoriasis Area and Severity Index PASI 100" },{" #name" :" keyword" ," $" :{" id" :" kwrd0145" }," $$" :[{" #name" :" text" ," _" :" 100% improvement in Psoriasis Area and Severity Index PSSD" },{" #name" :" keyword" ," $" :{" id" :" kwrd0155" }," $$" :[{" #name" :" text" ," _" :" Psoriasis Symptoms and Signs Diary PY" },{" #name" :" keyword" ," $" :{" id" :" kwrd0165" }," $$" :[{" #name" :" text" ," _" :" patient-year TNF" },{" #name" :" keyword" ," $" :{" id" :" kwrd0175" }," $$" :[{" #name" :" text" ," _" :" tumor necrosis factor TFR" },{" #name" :" keyword" ," $" :{" id" :" kwrd0185" }," $$" :[{" #name" :" text" ," _" :" treatment failure rules |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
